Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

SIMPLE SUMMARY: In this study, we measured the plasmatic concentration of Kinase inhibitors (KI) among a population with non-small cell lung cancer (NSCLC) harboring driver genetic alterations. They received erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Geraud, Arthur, Mezquita, Laura, Auclin, Edouard, Combarel, David, Delahousse, Julia, Gougis, Paul, Massard, Christophe, Jovelet, Cécile, Caramella, Caroline, Adam, Julien, Naltet, Charles, Lavaud, Pernelle, Gazzah, Anas, Lacroix, Ludovic, Rouleau, Etienne, Vasseur, Damien, Mir, Olivier, Planchard, David, Paci, Angelo, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764991/
https://www.ncbi.nlm.nih.gov/pubmed/33327482
http://dx.doi.org/10.3390/cancers12123758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764991/
https://www.ncbi.nlm.nih.gov/pubmed/33327482
http://dx.doi.org/10.3390/cancers12123758

Ejemplares similares